Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

E-ISSN： 1365-2036|42|2|188-202

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.2, 2015-07, pp. : 188-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vedolizumab for ulcerative colitis and Crohn's disease

PRESCRIBER, Vol. 26, Iss. 10, 2015-05 ,pp. : 22-24

John Wiley & Sons Inc

Access to resources Recommend Favorite

Crohn disease and colitis in children

JOURNAL OF PAEDIATRICS AND CHILD HEALTH, Vol. 51, Iss. 3, 2015-03 ,pp. : 266-270

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ulcerative colitis or Crohn's disease? Pitfalls and problems

HISTOPATHOLOGY, Vol. 64, Iss. 3, 2014-02 ,pp. : 317-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 4, 2015-04 ,pp. : 412-423

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 10, 2015-10 ,pp. : 979-979

John Wiley & Sons Inc

Access to resources Recommend Favorite